Travere Therapeutics Inc (TVTX)
22.09
-0.80
(-3.50%)
USD |
NASDAQ |
Mar 30, 16:00
22.08
-0.02
(-0.07%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.430B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -12.03% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.643 |
| Price to Book Value | 33.38 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 8.764 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 72.49% |
News
Headline
Wire
Time (ET)
Yahoo
03/14 17:00
Globe Newswire
03/14 17:00
Globe Newswire
02/28 22:36
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | -1.10 | -- | |
| 02/23/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/23/2023 | -- | Results | Q4 2022 | -0.76 | -0.84 | 9.25% | |
| 10/27/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 10/27/2022 | -- | Results | Q3 2022 | -0.76 | -0.70 | -7.86% | |
| 08/04/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.65 | -0.70 | 6.92% |
*Estimated Date/Time
Earnings
Profile
| Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
| URL | https://www.travere.com |
| Investor Relations URL | https://ir.travere.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 30, 2023.
Fundamentals
| Revenue (TTM) | 212.02M |
| Total Expenses (TTM) | 463.58M |
| Net Income (TTM) | -278.48M |
| Total Assets (Quarterly) | 672.58M |
| Total Liabilities (Quarterly) | 629.73M |
| Shareholders Equity (Quarterly) | 42.85M |
| Cash from Operations (TTM) | -186.29M |
| Cash from Investing (TTM) | -32.55M |
| Cash from Financing (TTM) | 117.57M |
Ratings
Profile
| Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
| URL | https://www.travere.com |
| Investor Relations URL | https://ir.travere.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| TVTX Tweets |